On June 11, 2020, Regeneron Pharmaceuticals initiated the first of its randomized, placebo-controlled clinical trials of REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19. Th e trials were conducted at multiple sites and consisted of four study populations—hospitalized COVID-19 patients, non- hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure, and uninfected people with close exposure to a COVID-19 patient. On September 20, the company announced the first data from the trials, which showed that REGN-COV2 reduced viral load and the time to alleviate symptoms in non-hospitalized patients. Th is trial also includes studies of REGN-COV2 for the treatment of hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19 patients.
Eli Lilly, which is also conducting late-stage trials of a similar treatment, has also released partial findings showing that its therapy may reduce virus levels. Both Regeneron and Lilly have requested emergency authorization from FDA, after President Trump’s fulsome praise for its effectiveness. Regeneron has been provided USD450 million through Operation Warp Speed (the U.S. program speeding corona virus vaccines and therapeutics development) to supply 300,000 treatment doses, or 1.3 million prevention doses, for Americans free of cost before the end of the year. Regeneron has entered into an agreement with Roche to boost manufacturing capacity that will result in between 4 million and 8 million doses. Similarly, Lilly has stated that it will be able to supply one million treatment doses before the end of the year.